Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs)-Reference-Cited by-同舟云学术

Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs)

Published:2017-09 Issue: Volume:60 Page:94-102
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Aggoune Djamel,Sorel Nathalie,Bonnet Marie-Laure,Goujon Jean-Michel,Tarte Karin,Hérault Olivier,Domenech Jorge,Réa Delphine,Legros Laurence,Johnson-Ansa Hyacinthe,Rousselot Philippe,Cayssials Emilie,Guerci-Bresler Agnès,Bennaceur-Griscelli Annelise,Chomel Jean-Claude,Turhan Ali G.

Funder

Novartis Oncology and Bristol-Myers Squibb

“Sport et Collection”

“Rotary Club de Civray”

Association Vaincre le Cancer – NRB, Villejuif, France

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference44 articles.

1. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors;Falchi;Am. J. Hematol.,2013

2. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV;Hehlmann;J. Clin. Oncol.,2014